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Impact of metformin treatment 
during pregnancy on maternal 
outcomes: a systematic review/
meta‑analysis
Jane L. Tarry‑Adkins1,2*, Susan E. Ozanne1 & Catherine E. Aiken1,2
We systematically assessed the impact of metformin treatment on maternal pregnancy outcomes. 
PubMed, Ovid Embase, Medline, Web of Science, ClinicalTrials.gov and Cochrane databases were 
systematically searched (inception‑1st February 2021). Randomised controlled trials reporting 
pregnancy outcomes in women randomised to metformin versus any other treatment for any 
indication were included. Outcomes included gestational weight gain (GWG), pre‑eclampsia, 
gestational hypertension, preterm birth, gestational age at delivery, caesarean section, gestational 
diabetes, glycaemic control, and gastrointestinal side‑effects. Two independent reviewers conducted 
screening, with a third available to evaluate disagreements. Risk‑of‑bias and GRADE assessments 
were conducted using Cochrane Risk‑of‑Bias and GRADE‑pro software. Thirty‑five studies (n = 8033 
pregnancies) met eligibility criteria. GWG was lower in pregnancies randomised to metformin versus 
other treatments (1.57 kg ± 0.60 kg;  I2 = 86%, p < 0.0001), as was likelihood of pre‑eclampsia (OR 0.69, 
95% CI 0.50–0.95;  I2 = 55%, p = 0.02). The risk of gastrointestinal side‑effects was greater in metformin‑
exposed versus other treatment groups (OR 2.43, 95% CI 1.53–3.84;  I2 = 76%, p = 0.0002). The risk of 
other maternal outcomes assessed was not significantly different between metformin‑exposed versus 
other treatment groups. Metformin for any indication during pregnancy is associated with lower GWG 
and a modest reduced risk of pre‑eclampsia, but increased gastrointestinal side‑effects compared to 
other treatments.
Metformin, an oral insulin-sensitizing and glucose-lowering drug, is widely prescribed during pregnancy. Guide-
lines from several global contexts, including the  UK1,2, New  Zealand3 and  Canada4 endorse metformin for the 
treatment of gestational diabetes mellitus (GDM). In the US, guidelines from the ADA and SMFM differ in their 
recommendations regarding the use of metformin as a first-line agent in pregnancy primarily because metformin 
crosses the placenta to the  fetus5. In low resource obstetric settings where some of the greatest increases in GDM 
are currently  observed6, metformin is commonly used in pregnancy it is relatively inexpensive and easily stored. 
Metformin is also used in pregnancy for other conditions, including pre-existing  diabetes7 and polycystic ovarian 
syndrome (PCOS)8, and has been trialled in the context of maternal  obesity9. However, despite the widespread 
prescription of metformin during pregnancy, data regarding maternal pregnancy outcomes are relatively sparse. 
In light of the recent ADA guidelines and meta-analyses specifically comparing GDM  treatments10–13, some 
clinicians are beginning to adopt a more cautious  approach14.
In the context of GDM, our previous study shows that metformin provides adequate glycaemic control in 
approximately two-thirds of patients who require pharmacological therapy, with the remaining 14–46% requiring 
additional treatment, usually  insulin12. Advantages of metformin include oral administration, cost-effectiveness, 
and suitability for use in low-resource  settings15. However, previous meta-analyses have raised concerns about the 
impacts of metformin on fetal and post-natal growth in the context of  GDM12,13. However maternal pregnancy 
outcomes are less well-studied, in women treated for conditions other than  GDM16,17. Randomised trials have 
reported potential maternal benefits associated with metformin treatment, including reduced gestational weight 
gain (GWG)18,19. Furthermore, mixed evidence suggests that pre-eclampsia rates may be reduced in women 
randomised to metformin  treatment20,21.
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Given the increasingly high number of women currently being prescribed metformin during pregnancy, 
we evaluated the impact of metformin treatment in pregnancy on the mother, by synthesizing all available ran-
domised trial data pertaining to common maternal outcomes (including gestational weight gain, pre-eclampsia, 
gestational hypertension, pre-term birth, gestational age at delivery, caeserean-section, glycaemic control, adverse 
events and GDM). These were investigated across the range of indications for which metformin is currently 
prescribed or trialled in pregnancy.
Materials and methods
This systematic review and meta-analysis was conducted in accordance with the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA)  guidelines22. The systematic review protocol was registered 
prospectively in PROSPERO CRD42020167692 on 14th February 2021 (Supplementary Text S1) prior to data 
collection. Ethical approval was not required for this meta-analysis.
Literature searches, search strategies and eligibility criteria. Systematic literature searches using 
pre-specified terms (Supplementary Text S2) were performed on PubMed, Ovid EMBASE, Ovid Medline, 
Cochrane library, Clinicaltrials.gov, and Web of Science from database inception dates to 14th February 2021. 
No language or location restrictions were applied. Studies that randomised pregnant women to metformin (not 
in combination with any other drug) versus any other drug treatment, placebo, or no treatment were included. 
Studies were included if they randomised pregnant women for any indication (including GDM, pre-existing 
diabetes, PCOS, or maternal obesity). All treatment indications were screened for and diagnosed according 
to local criteria in each study, and we did not apply exclusions with respect to this. Studies were excluded if 
they included participants with multiple pregnancies or if they randomised fewer than 50 women in total. Data 
reported in abstracts at society meetings or conferences would have been included if the abstract contained suf-
ficient information for assessment, but none fulfilled the criteria. Where insufficient information for assessment 
was available, authors were contacted for further information. One study provided insufficient information for 
assessment, however the authors did not respond to contact and therefore this study could not be included.
Study selection and data extraction. Two reviewers (JLA and CEA) independently assessed each study 
using pre-determined inclusion/exclusion criteria (Supplementary Table S2). A third reviewer (SEO) was avail-
able to resolve cases where eligibility was unclear. An initial screen of titles and abstracts was performed, fol-
lowed by a detailed full paper screen (Supplementary Fig. S1).
Data extraction from eligible studies was conducted independently using a standardised proforma by two 
authors (JLA and CEA). Maternal outcome measures were: gestational weight gain (GWG, throughout preg-
nancy; kg), pre-eclampsia, gestational hypertension (PIH), preterm birth (divided into spontaneous and iat-
rogenic), gestational age at delivery (weeks), caesarean section rates (divided into elective and emergency), 
glycaemic control (fasting blood glucose, FBG; mg/dL and random blood glucose, RBG; mg/dL), new GDM 
incidence, maternal hypoglycaemia, and any reported side-effects. All outcome measures were defined as per 
the original study criteria, and we did not apply any exclusion with respect to these.
Quality assessment (risk of bias). Each study was independently assessed by two authors (JLA and 
CEA) for quality and validity using the Cochrane Collaboration tool for assessing risk of bias. Seven risk of bias 
domains were systematically assessed for each study and each domain was given a rating of low risk, unknown 
risk or high risk of bias (Supplementary Table S3). All risk of bias analysis was conducted at the study level.
The principle summary measures were unadjusted odds ratios (OR) (for dichotomous data) or differences in 
means (for continuous data). Meta-analysis was performed using Review Manager (RevMan) Version 5.3, Copen-
hagen: The Nordic Cochrane Centre, the Cochrane Collaboration, 2014) and the ‘metafor’ package in R version 
3.5.1 (R Foundation for Statistical Computing, Vienna, Austria. Network meta-analysis was not implemented as 
the criteria for transitivity were not met by the set of included studies. Meta-regression was implemented to assess 
potential sources of inter-study heterogeneity (Supplementary Table S1). Funnel plots were constructed to assess 
publication bias. Meta-analyses with 5 or more studies included were also subjected to Egger’s test. Heterogeneity 
between studies was assessed using the I-squared statistic. Any outcomes demonstrating significant inter-study 
heterogeneity (heterogeneity p value < 0.05) were analysed using a random-effects model. Sensitivity analyses 
were performed using ‘leave-one-out’ sensitivity testing for individual studies. All outcomes were subjected to 
Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis (GRADEpro Guide-
line Development Tool, McMaster University, USA). Where the indication for randomisation was diabetes in 
pregnancy, the included studies all compared metformin to either insulin or glyburide, hence further sub-group 
analyses were performed by comparator group. Where the indication for randomisation was PCOS or obesity, all 
included studies compared metformin to placebo, therefore no further sub-group analyses were performed. A 
further sensitivity analysis excluding studies in which analysis was not performed on an intention-to-treat basis 
was also conducted. Where p values are reported, an alpha level < 0.05 was considered statistically significant.
Results
Study selection and study characteristics. The PRISMA flow chart (Supplementary Fig.  S1) dem-
onstrates the screening procedure involved to attain 35 studies (8033 participants) for this meta-analysis. The 
majority of these studies (27 studies; 5319 participants) investigated metformin treatment for diabetes in preg-
nancy (25 of these were women with GDM only and 2 studies included women with any type of diabetes in preg-
nancy). A total of 8 studies (2714 participants) investigated maternal obesity (4 studies; n = 1485) or PCOS (3 
studies; n = 930) or pre-gestational insulin resistance (1 study; n = 299). No studies investigated randomisation of 
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metformin compared to diet/lifestyle intervention alone, however these were commonly implemented alongside 
other treatments. Eligible studies were identified comparing metformin to insulin, glyburide, and placebo. For 
all indications and comparisons, the studies varied with respect to quality and design (Supplementary Table S1). 
The included studies demonstrated considerable heterogeneity with respect to the dosage of pharmacological 
agents (Supplementary Table S4). Heterogeneity also existed in the diagnostic criteria used for GDM and PCOS 
(Supplementary Table S5). The included studies came from a variety of geographical locations: Australasia (Aus-
tralia and New Zealand), Europe (the UK, Norway and Finland), North Africa/Middle East (Egypt, Iran and 
Israel) and the North America/Latin America (Canada, Mexico, Brazil and Chile).
Risk of bias and sensitivity analyses. The risk of bias was moderate-to-low in the majority of included 
studies, however six studies were considered to have a high risk of bias (Supplementary Table S3). We performed 
sensitivity analyses, excluding the studies assessed as having a high risk of bias (Supplementary Fig. S2), which 
showed that removal of studies with a high risk of bias did not materially alter the outcome of the meta-analyses 
for any of the outcomes, therefore all studies were included. Most studies reported non-significant differences 
in maternal baseline characteristics between groups (including maternal age, BMI and glycaemic control) (Sup-
plementary Table S4).
We assessed the likelihood of single studies significantly influencing the overall results using leave-one-out 
(LOO) analysis. For the primary comparison of metformin versus any other treatment across all indications, 
meta-analyses were robust to the omission of single studies (Supplementary Fig. S3), with the exception of cae-
sarean section, RBS, and maternal hypoglycaemia, decreasing our confidence in the robustness of these findings. 
Funnel plots for all outcomes were assessed visually (Supplementary Fig. S4); there were no obvious asymmetries 
in the plots for any study outcomes. Eggers testing demonstrated a low likelihood of publication bias with respect 
to the primary comparisons (Supplementary Table S6).
GRADE analysis (certainty of evidence). The majority of outcomes were classified as having a mod-
erate certainty of evidence (Supplementary Fig. S5; primary outcomes and Supplementary Fig. S6; secondary 
outcomes), with one outcome having a high certainty of evidence (gestational hypertension). The moderate 
certainty of evidence was ascertained from the majority of outcomes (5) having high heterogeneity (inconsist-
ency) of studies. All studies had no detected publication bias (as ascertained by the Eggers testing and funnel plot 
analyses). All studies reported direct evidence.
Synthesis of results. Gestational weight gain. Where the indication for randomisation was maternal 
obesity, there was on average 0.89  kg less GWG (p = 0.04) in metformin-treated women compared to those 
randomised to placebo (2  studies23,24 n = 813) (Fig. 1a). In the group where the indication for randomisation was 
PCOS, there was on average 2.4 kg less GWG (95% CI 3.38–1.42 kg;  I2 = N/A, p < 0.0001) in metformin-treated 
women compared to those randomised to placebo (1  study25 n = 398). In the group of women with diabetes in 
pregnancy, randomisation to metformin also resulted in significantly less GWG. Effect sizes were similar across 
all diabetes in pregnancy groups: − 1.57 kg for insulin (p = 0.0004) (7  studies26–32 n = 935) (Fig. 1b), − 1.67 kg for 
glyburide (p = 0.02) (3  studies33–35 n = 376) (Fig. 1c) and − 1.50 kg for placebo (95% CI − 2.39 to − 0.61,  I2 = N/A, 
p = 0.001) (1  study36 n = 482). This reduction in GWG was seen consistently across in all included groups (Sup-
plementary Fig. S7a). The 95% prediction interval for GWG across all groups was − 3.17 to 0.05 kg.
Pre‑eclampsia. There were no significant differences in the risk of pre-eclampsia where the indication for 
randomisation was maternal obesity (4  studies23,24,37,38, n = 1620) (Fig.  2a), PCOS (3  studies25,39,40 n = 818) 
(Fig. 2b) or diabetes in pregnancy. Effect sizes were similar across all diabetes in pregnancy groups: insulin (12 
 studies26–28,30,31,41–47 n = 3048) (Fig. 2c), glyburide (2  studies33,48 n = 253) (Fig. 2d) and placebo (OR 1.29, 95% CI 
0.77–2.16,  I2 = N/A, p = 0.34) (1  study36 n = 482). However in all groups, there was a clear trend towards a reduc-
tion in the likelihood of pre-eclampsia in women randomised to metformin compared to any other treatment. 
When all indications were combined, there was a significant reduction in the likelihood of pre-eclampsia in 
women randomised to metformin (OR 0.69, 95% CI 0.50–0.95;  I2 = 55%, p = 0.02) (Supplementary Fig. S7b); 
based on 23 studies including 6301 pregnancies. The 95% prediction interval was OR 0.24–1.99.
Gestational hypertension. There were no significant differences in the risk of gestational hypertension where 
the indication for randomisation was maternal obesity (3  studies23,24,37 n = 1354) (Fig. 3a), PCOS (OR 1.26, 95% 
CI 0.59–2.68;  I2 = N/A, p = 0.55) (1  study25 n = 478) or diabetes in pregnancy. Effect sizes were similar across all 
diabetes in pregnancy groups: insulin (8  studies26,28,31,32,41,43,45,46, n = 1716) (Fig. 3c), glyburide (OR 1.16, 95% 
CI 0.42–3.17,  I2 = N/A, p = 0.34) (1  study49, n = 159) or placebo (OR 0.87, 95% CI 0.40–1.86;  I2 = N/A, p = 0.71) 
(1  study36, n = 482). In contrast to the finding with respect to pre-eclampsia, there was no difference in the 
likelihood of PIH between women randomised to metformin versus any other treatment when all studies were 
combined (OR 0.95, 95% CI 0.77–1.18;  I2 = 0%, p = 0.66) (Supplementary Fig. S7c) based on 16 studies including 
4189 pregnancies. The 95% prediction interval was OR 0.78–1.19.
In view of the heterogeneity of definitions that are used globally for pre-eclampsia and gestational hyperten-
sion, we also conducted an overall meta-analysis of all reported hypertensive disease of pregnancy outcomes. 
Women who were randomised to metformin v. any other treatment had a significantly decreased risk of any 
hypertensive disease of pregnancy (OR 0.76, 95% CI 0.60–0.95;  I2 = 47%, p = 0.01) (Supplementary Fig. S7d); 
based on 23 studies including 11,145 pregnancies.
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Preterm birth (any‑cause, spontaneous and iatrogenic). There were no significant differences in the risk of any-
cause preterm birth in the sub-group analyses where the indication for randomisation was maternal obesity (4 
 studies23,24,37,38 n = 1620) (Fig. 4a) or diabetes in pregnancy. Effect sizes were similar across all diabetes in preg-
nancy groups: insulin (15  studies28,31,32,41–47,50–54, n = 3519) (Fig. 4b), glyburide (3  studies33,35,49, n = 463) (Fig. 4c) 
and placebo (OR 1.35, 95% CI 0.87–2.09;  I2 = 0%, p = 0.18) (1  study36, n = 461). However, in the sub-group where 
the indication for randomisation was PCOS (3  studies25,39,40 n = 827) (Fig. 4d), randomisation to metformin was 
associated with reduced likelihood of preterm birth (p = 0.01). Insufficient studies were available to meaningfully 
perform planned analyses with respect to spontaneous versus iatrogenic preterm birth. There was no difference 
in the overall likelihood of preterm birth between women randomised to metformin versus other interventions 
(Supplementary Fig. S7d) based on 27 studies including 7043 pregnancies. The 95% prediction interval was OR 
0.31–2.64.
Gestational age at delivery. There was no significant difference in gestational age at delivery where the indica-
tion for randomisation was maternal obesity (2  studies23,24 n = 948) (Fig. 5a) or diabetes in pregnancy. Effect sizes 
were similar between all diabetes in pregnancy groups: insulin (12  studies26–31,43,45–47 n = 2345) (Fig. 5b), glybur-
ide (4  studies33–35,48 n = 525) (Fig. 5c). No studies reported gestational age at delivery in the sub-group of women 
with PCOS. Randomisation to metformin versus any other treatment did not significantly influence gestational 
age at delivery, based on 17 studies including 3803 pregnancies (Supplementary Fig. S7e). The 95% prediction 
interval was − 0.48 to 0.32 weeks.
Caesarean section (all cause, emergency and elective). In the sub-group where the indication for randomisa-
tion was maternal obesity (3  studies23,24,37 n = 1352), randomisation to metformin (versus placebo) was associ-
ated with reduced likelihood (p = 0.03) of caesarean section (Fig. 6a). Where the indication for randomisation 
was PCOS (2  studies25,40 n = 1352) (Fig. 6b) or diabetes in pregnancy randomisation to metformin versus other 
treatments did not alter likelihood of caesarean section. Effect sizes were similar between all diabetes in preg-
nancy groups: insulin (17  studies26–32,41,42,44,46,47,50–52,55,56 n = 2872) (Fig. 6c), glyburide (5  studies33–35,48,49, n = 684) 
(Fig. 6d) and placebo (OR 0.68, 95% CI 0.47–1.00;  I2 = N/A, p = 0.05) (1  study36, n = 470). When analysis was per-
formed combining all indications for metformin treatment, there was a lower likelihood of delivery by caesarean 
section in women randomised to metformin versus other treatments (OR 0.90, 95% CI 0.82–1.00;  I2 = 23%, 
p = 0.04) (Supplementary Fig. S7f) based on 31 studies including 7053 pregnancies. When sub-group analysis 
was performed separating emergency and elective caesarean section, there was no significant effect of randomi-
Figure 1.  Effect of metformin randomisation upon gestational weight gain (throughout pregnancy); (all 
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sation to metformin versus other treatments on likelihood of either type of caesarean section (Supplementary 
Fig. S7g and S7h). The 95% prediction interval was OR 0.66–0.78.
Side‑effects. Randomisation to metformin versus placebo for any indication during pregnancy was associated 
with increased likelihood of nausea, vomiting and diarrhoea, but not abdominal pain or non-gastrointestinal 
side-effects (Supplementary Table S7). Nausea, vomiting, and diarrhoea were all significantly increased when 
the indication for metformin randomisation was maternal obesity (Table 1). However, when the indication for 
randomisation was PCOS, fewer studies were available for analysis and only the likelihood of diarrhoea was 
significantly increased with metformin versus placebo (Table 1). Trials involving women with diabetes in preg-
nancy either did not report gastrointestinal side effects in the insulin arm, or reported zero values. Between 2 
and 46% of women randomised to metformin for treatment of diabetes in pregnancy reported gastrointestinal 
Figure 2.  Effect of metformin randomisation upon pre-eclampsia (all indications), based on 21 studies 
including 5979 pregnancies. Odds ratio, random-effects model, 95% CI.
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side-effects (weighted average incidence 12.5%; Supplementary Table S8) and 0–6% of women stopped medica-
tion due to these side effects (weighted average incidence 14.3%), (Supplementary Table S8).
GDM in participants randomised for indications other than diabetes. Randomisation to metformin versus any 
other treatment (placebo) did not alter the likelihood of subsequent GDM diagnosis (OR 1.07, 95% CI 0.87–
1.33;  I2 = 0%, (p = 0.52) (Supplementary Fig. S8), based on 7 studies including 2063 pregnancies. Whether the 
indication for randomisation was maternal obesity (3  studies23,24,37 n = 1206) or PCOS (3  studies25,39,40 n = 746) 
(Supplementary Fig. S8), randomisation to metformin did not alter likelihood of GDM.
Glycaemic control in diabetes in pregnancy. There was no significant difference in FBS (19 studies, n = 3673) 
(Supplementary Fig.  S9a) or RBS (18 studies, n = 3610) (Supplementary Fig.  S10a) measurements in women 
with diabetes in pregnancy randomised to metformin versus other treatments. Effect sizes were similar and 
non-significant in all diabetes in pregnancy sub-groups: FBS: insulin (14  studies26–28,31,32,41–46,50,51,56 n = 2945), 
glyburide (4  studies33–35,48, n = 525) (Supplementary Fig.  S9b and c), and placebo (1  study36, n = 140) (OR 
− 2.40, 95% CI − 6.98 to 2.18;  I2 = N/A, p = 0.30). RBS: insulin (12  studies26–28,31,41–45,47,51,56, n = 2895), glyburide 
(4  studies33–35,48 n = 525) (Supplementary Fig. S10b and c), and placebo (1  study36 n = 125), (OR-1.20, 95% CI 
−  6.82 to 4.42;  I2 = N/A, p = 0.68). Maternal hypoglycaemia was significantly (p = 0.005) less likely in women 
randomised to metformin versus other treatments (Supplementary Fig. S11a), based on 6 studies including 1149 
 pregnancies32,36,47,48,51,55, however this effect is driven entirely by studies where insulin was the comparator group 
(Supplementary Fig. S11b).
Discussion
Our results demonstrate that exposure to metformin versus other treatments during pregnancy reduced GWG, 
an effect consistently observed across all indications and sensitivity analyses. The likelihood of developing pre-
eclampsia was reduced in women randomised to metformin in all treatment indication sub-groups. This did 
not reach statistical significance likely because of insufficient data when each indication for treatment was con-
sidered separately. However both the direction and the magnitude of the observed change was similar across all 
sub-groups of indications for metformin treatment. No difference in the incidence of gestational hypertension, 
gestational age at delivery or glycaemic control (irrespective of indication) was observed in any treatment indica-
tion sub-group. Randomisation to metformin in women with obesity (compared to placebo) was associated with 
significant reduction in the likelihood of cesarean section. Significantly reduced likelihood of preterm birth was 
only observed in women with PCOS randomised to metformin compared with placebo. Women randomised to 
metformin versus insulin for treatment of diabetes in pregnancy had a significantly lower likelihood of experienc-
ing hypoglycaemia. However the likelihood of gastrointestinal symptoms (nausea, vomiting and diarrhoea) was 
significantly increased in women randomised to metformin versus other treatments. The incidence of GDM was 
Figure 3.  Effect of metformin randomisation upon gestational hypertension (all indications), based on 14 
studies including 4189 pregnancies. Odds ratio, fixed-effects model, 95% CI.
7
Vol.:(0123456789)
Scientific Reports |         (2021) 11:9240  | https://doi.org/10.1038/s41598-021-88650-5
www.nature.com/scientificreports/
not significantly different in metformin-treated compared to other treatment groups, hence metformin is unlikely 
to be of benefit as a preventative measure against GDM (where GDM was not the indication for treatment).
A major strength of this study is the breadth of outcomes affecting women during pregnancy that have been 
included. Our focus on maternal outcomes complements our previous work performed on fetal and childhood 
 outcomes12,13. We also performed extensive sub-group and sensitivity evaluation of our conclusions.
Figure 4.  Effect of metformin randomisation upon pre-term birth (all indications). (a) All-cause (based on 27 
studies including 6959 pregnancies), (b) spontaneous (based on 4 studies including 2308 pregnancies) and (c) 
iaotrogenic (based on 5 studies including 2050 pregnancies). Odds ratio, (95% CI). Fixed-effects model for (a) 
and (b), random-effects model for (c).
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The drawing of definitive conclusions from our meta-analysis is limited by both the quantity and quality of 
the studies available. In particular, there was a paucity of trials randomising women with PCOS (3 studies, n = 930 
women) or maternal obesity (4 studies, n = 1485 women), limiting our confidence in conclusions relating specifi-
cally to treatment for these indications and therefore we urge a conservative view with regard to interpretation 
of this sub-group analyses. No randomised trials were found that compared metformin specifically with dietary/
lifestyle intervention, although several studies included these interventions for both trial arms. Our search results 
highlight the need for more high-quality studies investigating metformin use during pregnancy. A further reason 
for caution in interpretation is the high heterogeneity in dose, GDM diagnosis criteria and starting point during 
gestation of metformin treatment between the various included studies.
Overall, metformin use during pregnancy is associated with a greater risk of experiencing gastrointestinal 
side-effects than placebo or other treatments. Gastrointestinal symptoms are reported in 20–30% of patients 
treated with metformin outside of  pregnancy57,58. A variety of mechanisms are proposed including bile-salt mal-
absorption, gut serotonin secretion, and alterations to glucose and incretin  metabolism58. These symptoms may 
be more common in  women59 and more difficult to tolerate during pregnancy due to concomitant pregnancy-
related nausea, vomiting, and food  aversions59,60.
Clear evidence of benefit from randomisation to metformin observed in all sub-groups is limited to a reduc-
tion in GWG, which may be related to direct actions of metformin which can inhibit food intake, via increased 
concentration of growth/differentiation-factor-15 (GDF15)61. Excessive GWG is associated with perinatal com-
plications including increased risk of fetal growth anomalies, risk of GDM, cesarean delivery and pre-eclamp-
sia36,62. Moreover, increased GWG is associated with long-term (later in life) health risks to the mother including 
post-partum weight retention,  obesity63,64 and increased risk of developing type 2  diabetes65 and cardiovascular 
 disease66. Limiting GWG may also improve outcomes for future  pregnancies67. The average weight gain observed 
in pregnancies affected by GDM is approximately 9  kg62 therefore a reduction of 1.55 kg (17%, as observed here) 
constitutes a potentially clinically significant reduction in total GWG. The observed reduction in GWG for 
women randomised to metformin in studies of maternal obesity was smaller (0.89 kg vs. 1.55 kg overall), which 
likely reflects the increased likelihood of lower GWG in obese  women68.
Figure 5.  Effect of metformin randomisation upon gestational age at delivery (all indications), (based on 18 
studies including 3818 pregnancies). Odds ratio (95% CI), random-effects model.
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Figure 6.  Effect of metformin randomisation upon caesarean section (all indications). (a) All cause, (based on 
29 studies including 6122 pregnancies), (b) emergency (based on 7 studies including 1772 pregnancies) and (c) 
elective (based on 5 studies including 1552 pregnancies). Odds ratio (95% CI). Random-effects model for (a) 
and (b). Fixed-effects model for (c).
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The likelihood of pre-eclampsia was non-significantly reduced in women with diabetes in pregnancy ran-
domised to metformin versus insulin. This is in keeping with other recent  studies11, although previous findings 
were limited only to analysis of women with GDM. Other studies have reported a higher incidence of pre-
eclampsia in women with GDM compared to those with normal glucose  tolerance69,70; it is thus possible that 
any impact of metformin in reducing the likelihood of pre-eclampsia may be more readily detectable in popula-
tions with higher baseline risk. Mechanistically, it is plausible that metformin could prevent pre-eclampsia via 
reduction of anti-angiogenic factors, improvements of endothelial function via actions on the mitochondria 
and/or via actions through the mammalian target of rapamycin (mTOR) pathway by modification of cellular 
homeostasis and energy  deposition70. These potential mechanisms are supported by the fact that metformin does 
not appear to influence the risk of gestational hypertension, which is associated only with hypertension rather 
than multisystem end-organ  involvement71,72 [16230510] often attributed to wide-spread maternal endothe-
lial and metabolic  dysfunction73 [33189710]. Previous meta-analyses have explored the impact of metformin 
on pre-eclampsia risk, with mixed  results20,21,71. Our work builds on these, with the inclusion of several more 
recently published  studies10,11. At least one previous meta-analysis that included both GDM and non-GDM 
pregnancies and analysed both randomised and observational  data72 found no significant effect of metformin 
on pre-eclampsia risk. We note the wide 95% prediction interval associated with our meta-analysis, reflecting 
the relatively high heterogeneity between included studies and the possibility that future studies on this topic 
could find significantly different results.
Our finding that metformin reduces the rate of cesarean section in obese women but not in other sub-groups 
may relate to our previous finding of lower birth weight associated with randomisation to  metformin15, as there is 
increased likelihood of vaginal delivery with smaller fetuses. Maternal obesity is associated with increased birth 
 weight67 hence the impact of metformin in reducing fetal size and thus decreasing the risk of cesarean section 
may be amplified in this sub-group.
In weighing the risks and benefits of metformin treatment in pregnancy to the materno-fetal dyad, our 
meta-analysis highlights largely neutral or positive maternal outcomes, with the notable exception of increased 
likelihood of gastrointestinal side effects. There was no effect of metformin in reducing the risk of developing 
GDM, and metformin may not be adequate pharmacological treatment for GDM in up to 46% of  women12. From 
the fetal point of view however, it has previously been demonstrated that randomisation to metformin treatment 
for GDM is associated with increased risk of low birth-weight followed by accelerated growth in  childhood12,13, 
independent of maternal glycaemic  control13. It is particularly important to carefully consider the impacts of 
metformin treatment on both mother and baby as there are other suitable alternative treatments for GDM and 
no necessity for drug treatment for PCOS or maternal obesity in pregnancy. Moreover, there are other methods 
of controlling GWG, for example diet and lifestyle modification. Individual pregnant women may weigh the 
importance of limiting gestational weight gain or of avoiding gastrointestinal symptoms differently, and these 
findings may thus influence decision-making around metformin treatment in pregnancy.
Data availability
The data for this meta-analysis are freely available. The PROSPERO protocol can be found at https:// www. crd. 
york. ac. uk/ prosp ero CRD ID: CRD42020167692.
Table 1.  Effect of metformin intervention upon common side effects in women with maternal obesity/PCOS.
Effect size estimate (95% CI) or OR 
(95% CI) p value Studies N Het  I2 Het. p value
Overall GI side effects Placebo 2.43 (1.53–3.84) 0.0002 4 1441 76% 0.006
Nausea
Maternal obesity 1.43 (1.11–1.84) 0.006 3 1201 36% 0.21
PCOS 1.60 (0.75–3.45) 0.23 1 240 N/A N/A
Vomiting
Maternal obesity 1.41 (1.08–1.83) 0.01 3 1201 35% 0.22
PCOS 1.85 (0.45–7.58) 0.39 1 240 N/A N/A
Diarrhoea
Maternal obesity 2.34 (1.39–3.94) 0.001 3 1201 67% 0.05
PCOS 6.47 (2.17–19.29) 0.0008 1 240 N/A N/A
Abdominal pain
Maternal obesity 0.98 (0.66–1.44) 0.91 3 1201 0% 0.99
PCOS 0.50 (0.19–1.32) 0.16 1 240 62% 0.11
Bloating
Maternal obesity NO STUDIES – – – – –
PCOS 1.32 (0.73–2.38) 0.36 1 240 N/A N/A
Constipation
Maternal obesity 1.11 (0.76–1.63) 0.59 3 797 15% 0.28
PCOS NO STUDIES – – – –
Headache
Maternal obesity 1.17 (0.82–1.69) 0.39 2 797 69% 0.07
PCOS NO STUDIES – – – – –
GDM
Maternal obesity 1.16 (0.68–1.96) 0.59 2 1208 68% 0.08
PCOS 1.00 (0.71–1.42) 0.99 3 746 0% 0.54
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